BICOLL owns small molecule, property-based isolation technologies to identify beneficial compounds (Bifrac N™ and Bipreselect™). These technologies turn plant extracts into promising sets of small molecules, so-called plant “Profiles™”. These compounds can be selected and assembled according to the test system and are fully compatible with HTS and cell based assay systems.
Dedicated to the discovery and optimization of the highest quality lead compounds, BICOLL provides an efficient, multi-disciplinary approach to drug discovery.
With further innovative strategies supported by its proprietary in-house technology platform, BICOLL is able to rapidly select only the best leads with superior drug-like profiles for the further development cycles. Subsequent medicinal chemistry and custom synthesis complete BICOLL’s seamless substantial services for the global pharmaceutical and biotech industries.
Drug discovery: Most successful source – 80 % Top-200 Drugs >>
Orphan targets: From initial screening to animal data: 9-month >>
Rare diseases: German Patent 10 2005 027 796.9 >>
Screening: Isolation of Anti-HIV compounds >>
Lead generation: Synthesis of CRHR1 antagonist DMP696 >>
Lead optimization: US$20 million EU funded project >>
Food additives: Natural product communications, 2015, Vol. 10(4), 597 – 603 >>